On computer‐intensive simulation and estimation methods for rare‐event analysis in epidemic models
暂无分享,去创建一个
Stéphan Clémençon | Viet Chi Tran | Anthony Cousien | Miraine Dávila Felipe | S. Clémençon | V. Tran | A. Cousien
[1] Nando de Freitas,et al. Sequential Monte Carlo Methods in Practice , 2001, Statistics for Engineering and Information Science.
[2] Paul Glasserman,et al. Multilevel Splitting for Estimating Rare Event Probabilities , 1999, Oper. Res..
[3] Alexander Grey,et al. The Mathematical Theory of Infectious Diseases and Its Applications , 1977 .
[4] Viet Chi Tran,et al. HIV with contact tracing: a case study in approximate Bayesian computation. , 2008, Biostatistics.
[5] J. Desenclos,et al. [Risk factors for hepatitis C virus transmission to Health Care Workers after occupational exposure: a European case-control study]. , 2005, Revue d'epidemiologie et de sante publique.
[6] E. Volz. SIR dynamics in random networks with heterogeneous connectivity , 2007, Journal of mathematical biology.
[7] Pieter-Tjerk de Boer,et al. Techniques for simulating difficutl queueing problems: adaptive importance sampling simulation of queueing networks , 2000, WSC '00.
[8] Gerardo Rubino,et al. Introduction to Rare Event Simulation , 2009, Rare Event Simulation using Monte Carlo Methods.
[9] F. Cérou,et al. Adaptive Multilevel Splitting for Rare Event Analysis , 2007 .
[10] F. Gland,et al. Genetic genealogical models in rare event analysis , 2006 .
[11] W. O. Kermack,et al. A contribution to the mathematical theory of epidemics , 1927 .
[12] Louisa Degenhardt,et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.
[13] Stéphan Clémençon,et al. The HIV/AIDS epidemic in Cuba: description and tentative explanation of its low HIV prevalence , 2007, BMC infectious diseases.
[14] Reuven Y. Rubinstein,et al. Optimization of computer simulation models with rare events , 1997 .
[15] Valerie Isham,et al. Stochastic Models for Epidemics with Special Reference to AIDS , 1993 .
[16] Thomas Berg,et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. , 2014, The New England journal of medicine.
[17] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[18] D. Vere-Jones. Markov Chains , 1972, Nature.
[19] Paul Dupuis,et al. The design and analysis of a generalized RESTART/DPR algorithm for rare event simulation , 2011, Ann. Oper. Res..
[20] P. Moral. Feynman-Kac Formulae: Genealogical and Interacting Particle Systems with Applications , 2004 .
[21] Shie Mannor,et al. A Tutorial on the Cross-Entropy Method , 2005, Ann. Oper. Res..
[22] M. S. Bartlett,et al. Some Evolutionary Stochastic Processes , 1949 .
[23] Agnès Lagnoux,et al. RARE EVENT SIMULATION , 2005, Probability in the Engineering and Informational Sciences.
[24] Peter W. Glynn,et al. Stochastic Simulation: Algorithms and Analysis , 2007 .
[25] Albert D Donnenberg,et al. Rare-event analysis in flow cytometry. , 2007, Clinics in laboratory medicine.
[26] Stéphan Clémençon,et al. A stochastic SIR model with contact-tracing: large population limits and statistical inference , 2008, Journal of biological dynamics.
[27] John McNally,et al. Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.
[28] P. Moral,et al. Branching and interacting particle systems. Approximations of Feynman-Kac formulae with applications to non-linear filtering , 2000 .
[29] Philippe Picard,et al. A non-standard family of polynomials and the final size distribution of Reed-Frost epidemic processes , 1990, Advances in Applied Probability.
[30] Joseph Gani,et al. Stochastic Epidemic Models and Their Statistical Analysis , 2002 .
[31] G. Dore,et al. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Charles J. Mode,et al. Stochastic Processes in Epidemiology: Hiv/Aids, Other Infectious Diseases and Computers , 2000 .
[33] L. Decreusefond,et al. Large graph limit for an SIR process in random network with heterogeneous connectivity , 2010, 1007.3958.
[34] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.
[35] G. Roberts,et al. Bayesian inference for partially observed stochastic epidemics , 1999 .
[36] James A. Bucklew,et al. Introduction to Rare Event Simulation , 2010 .
[37] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[38] P. Moral,et al. Genealogical particle analysis of rare events , 2005, math/0602525.
[39] Stefano Giordano,et al. Rare event simulation , 2002, Eur. Trans. Telecommun..
[40] W. Dowdle. The principles of disease elimination and eradication. , 1998, Bulletin of the World Health Organization.
[41] Vivek S. Borkar,et al. Adaptive Importance Sampling Technique for Markov Chains Using Stochastic Approximation , 2006, Oper. Res..